MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$90,000K
Proceeds from issuance of
common stock under...
$115K
(25.00%↑ Y/Y)
Proceeds from issuance of
common stock in...
$85K
Net cash provided by
(used in) financing...
$85,820K
(69872.36%↑ Y/Y)
Canceled cashflow
$4,380K
Net (decrease)
increase in cash, cash...
$4,743K
(-64.28%↓ Y/Y)
Canceled cashflow
$81,077K
Payment of offering
costs
$4,367K
Payment of withholding
taxes related to...
$13K
(85.71%↑ Y/Y)
Proceeds from maturities
of marketable...
$24,463K
(-77.33%↓ Y/Y)
Stock-based compensation
$2,027K
(-73.49%↓ Y/Y)
Accrued expenses and
other liabilities
$1,921K
(191.56%↑ Y/Y)
Noncash lease expense
$390K
(-49.15%↓ Y/Y)
Depreciation and
amortization
$353K
(-59.33%↓ Y/Y)
Net cash (used in)
provided by investing...
-$65,503K
(-188.87%↓ Y/Y)
Net cash used in
operating activities
-$15,574K
(74.18%↑ Y/Y)
Canceled cashflow
$24,463K
Canceled cashflow
$4,691K
Purchases of marketable
securities
$89,966K
(163.62%↑ Y/Y)
Net loss
-$13,921K
(78.01%↑ Y/Y)
Deferred revenue
-$5,704K
Amortization of premium and
discount on marketable...
$313K
(133.58%↑ Y/Y)
Accounts payable
-$154K
(94.42%↑ Y/Y)
Prepaid expenses and
other current assets
$102K
(-92.60%↓ Y/Y)
Operating lease
liabilities
$71K
(171.00%↑ Y/Y)
Back
Back
Cash Flow
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)
source: myfinsight.com